NDATOPICALCREAM
Approved
Dec 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ELIDEL (pimecrolimus) by Bausch + Lomb is calcineurin inhibitors [moa]. Approved for calcineurin inhibitor immunosuppressant [epc]. First approved in 2001.
Drug data last refreshed 13h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELIDEL (pimecrolimus) is a topical calcineurin inhibitor cream approved in 2001 for treating atopic dermatitis and other inflammatory skin conditions. It works by suppressing T-cell activation and cytokine production at the skin level without systemic immunosuppression. The drug represents a non-steroidal alternative for patients requiring long-term topical anti-inflammatory therapy.
$0.87MPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with minimal commercial momentum; limited headcount growth expected as brand transitions to maintenance mode.
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
Started Oct 2024
130 enrolled
Mild to Moderate Atopic Dermatitis
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Started Apr 2024
477 enrolled
Blepharitis
Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
Started Mar 2021
130 enrolled
Atopic Dermatitis
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
Started Feb 2016
654 enrolled
Atopic Dermatitis
Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema
Started Oct 2009
40 enrolled
Atopic Dermatitis
Worked on ELIDEL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.